This Article  • Full text  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (32)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Immunization  • Alert me on articles by topic

Ra K. Han, MD; Earl D. Silverman, MD; Alice Newman, MSc; Brian W. McCrindle, MD, MPH

Arch Pediatr Adolesc Med. 2000;154:694-699.

Objective  To determine differences in clinical characteristics, laboratory findings, and cardiac complications between patients with acute Kawasaki disease who received additional treatment for persistent or recurrent fever vs those who did not.

Design  Nonconcurrent case series; medical record review.

Setting  Tertiary care pediatric hospital.

Patients  One hundred eighty-five consecutive patients diagnosed as having acute Kawasaki disease at The Hospital for Sick Children, Toronto, Ontario, from 1995 to 1997.

Main Outcome Measure  Prevalence of cardiac complications.

Results  Twenty-one patients (11%) received additional treatment with intravenous gamma globulin (IVGG) with or without intravenous methylprednisolone for persistent fever lasting for more than 48 hours or recurrent fever after initial treatment with IVGG. Patients who received additional treatment did not differ significantly from other patients regarding age, sex, race, or diagnostic criteria. Compared with the patients who did not receive additional therapy, the patients who received additional treatment had shorter median interval from fever onset to initial dose of IVGG (5 vs 6 days; P=.006) and longer total days of fever (9 vs 6 days; P<.001). Initial laboratory investigations did not differ significantly. On initial echocardiography, patients who received additional therapy were significantly more likely to have pericardial effusion (33% vs 15%; P=.04), ventricular dysfunction (14% vs 2%; P=.002), and coronary artery ectasia (76% vs 43%; P=.004) but not aneurysms (10% vs 5%; P=.47). At 12 months after diagnosis, there were no significant differences between the 2 groups regarding the prevalence of coronary artery ectasia or aneurysms.

Conclusion  Patients receiving additional treatment for persistent or recurrent fever have similar demographic and clinical characteristics, greater initial cardiac involvement, and similar overall outcomes.

From the Divisions of Cardiology (Drs Han and McCrindle and Ms Newman) and Rheumatology (Dr Silverman), Department of Pediatrics, University of Toronto, The Hospital for Sick Children, Toronto, Ontario.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prevalence of Coronary Artery Lesions on the Initial Echocardiogram in Kawasaki Syndrome
Baer et al.
Arch Pediatr Adolesc Med 2006;160:686-690.
ABSTRACT | FULL TEXT  

Infections and Kawasaki Disease: Implications for Coronary Artery Outcome
Benseler et al.
Pediatrics 2005;116:e760-e766.
ABSTRACT | FULL TEXT  

Treatment of Acute Kawasaki Disease: Aspirin's Role in the Febrile Stage Revisited
Hsieh et al.
Pediatrics 2004;114:e689-e693.
ABSTRACT | FULL TEXT  

Coronary risk factors in Kawasaki disease treated with additional gammaglobulin
Miura et al.
Arch. Dis. Child. 2004;89:776-780.
ABSTRACT | FULL TEXT  

Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research
Brogan et al.
Arch. Dis. Child. 2002;86:286-290.
ABSTRACT | FULL TEXT